Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today
Neer Varshney, 23 March 2021
The shares of Benitec Biopharma Inc BNTC 1.02% are trading 92.5% higher at $6.14 in the early pre-market session on Tuesday. What Happened: Benitec shares had closed at $3.19 on Monday. The surge follows Morgan Stanley MS 0.49% disclosing in a filing with the U.S. Securities and Exchange Commission after the markets closed on Monday that it had increased its stake by about 5.2% in the Australian biotechnology company.
Morgan Stanley disclosed in the 13G filing it now owned 249,174 shares in Benitec, compared to about 13,100 earlier.
Benitec is engaged in providing gene silencing therapies, combining RNA interference with gene therapy.
Read Full Article
Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study
PRNewswire, 08 July 2020
Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the initiation of the BB-301 Tissue Transduction Study in large animal subjects. Continue reading “Article: Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study”
Should You Be Concerned About Benitec Biopharma Limited’s (NASDAQ:BNTC) Historical Volatility?
Simply Wall St, 20 April 2020
Anyone researching Benitec Biopharma Limited (NASDAQ:BNTC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market. Continue reading “Article: Should You Be Concerned About Benitec Biopharma Limited’s (NASDAQ:BNTC) Historical Volatility?”
Benitec: The Health Payer’s Dream Biotech
Pannobhaso, 12 March 2014
When it comes to forecasting the size of the market for drugs to treat various diseases, the estimates for the same disease can seem to fluctuated wildly depending on the model used and the timeframe of the forecast. However, one thing that is fairly consistent is that for many of the major diseases, these forecasts involve big numbers – billions of dollars. However, as a guide to pharmaceutical earnings, these forecasts are meaningless if health payers cannot afford the costs. Continue reading “Article: Benitec: The Health Payer’s Dream Biotech”
Thinking about buying stock in Sundial Growers, Liquid Media, Benitec Biopharma, Evolve Transition Infrastructure, or Zomedica?
PRNewswire, 23 March 2011
NEW YORK, March 23, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for SNDL, YVR, BNTC, SNMP, and ZOM.
To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link. Continue reading “Article: Thinking about buying stock in Sundial Growers, Liquid Media, Benitec Biopharma, Evolve Transition Infrastructure, or Zomedica?”